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Long-term combined treatment with thiazide and potassium sium wasting. Even mild degrees of potassium depletion
citrate in nephrolithiasis does not lead to hypokalemia or hypo- can lead to intracellular acidosis and hypocitraturia [4, 5]
chloremic metabolic alkalosis.
that offset the therapeutic advantage of lowering urinaryBackground. Potassium citrate is commonly used in combi-
calcium. Therefore, thiazide therapy invariably obligatesnation with a thiazide diuretic in the medical management of
recurrent hypercalciuric nephrolithiasis. However, concerns some form of potassium replacement. Potassium citrate in
have been raised that administration of this nonchloride potas- combination with a thiazide diuretic has been shown to be
sium alkali with a kaliuretic and natriuretic agent such as thia-
useful in the medical management of recurrent hypercal-zide may not be efficacious in correcting or preventing hypoka-
ciuric nephrolithiasis [6]. In addition to the replenishinglemia, and may produce hypochloremic metabolic alkalosis.
This retrospective analysis was conducted to determine if these of potassium, potassium citrate has the added advantage
two potential complications are encountered in patients on of increasing urinary pH and urinary citrate, rendering
long-term potassium citrate and thiazide therapy.
it a suitable agent in the medical management of patientsMethods. Data were collected on 95 patients who had been
with hypercalciuric nephrolithiasis taking thiazide.on combination therapy for at least 4 months from the stone
clinics of the University of Texas Southwestern Medical Center, Two concerns have been raised about using an alkali
Duke University Medical Center, and Ochsner Clinic. organic anion such as citrate rather than chloride as part of
Results. Mean serum potassium concentration remained
the potassium supplement for patients on long-term thia-within normal limits without a significant decrease during com-
zide therapy. First, potassium from potassium chloridebined therapy. Serum chloride was significantly lower from
pretreatment but by only 1 mEq/L and remained within normal is much better retained than from potassium citrate or
limits throughout treatment. There was a small increase in bicarbonate, rendering patients on potassium citrate more
serum bicarbonate concentration compared to the baseline
prone to develop chronic potassium depletion [7]. Sec-level of less than 1 mEq/L at 8 to 12 and 18 to 24 months, but
ond, an alkali given in conjunction with a natriureticnot at other treatment periods.
Conclusion. Co-administration of potassium citrate did not may increase the risk for the development of metabolic
induce hypokalemia or hypochloremic metabolic alkalosis in alkalosis [8]. Theoretically, these complications, if pres-
our thiazide-treated patient population.
ent, may negate the advantages of potassium citrate
stated above.
This retrospective analysis was undertaken to specifi-Thiazide diuretics are commonly used for the preven-
cally determine if administration of potassium citratetion of recurrent calcium oxalate nephrolithiasis [1, 2]
is effective in preventing thiazide-induced hypokalemiaowing to their hypocalciuric action [3]. Inherent in the
and whether there is any evidence of metabolic alkalosis.therapeutic effects of thiazide diuretics is urinary potas-
Data on 95 patients were analyzed from medical records
from three centers specializing in the care of patientsKey words: thiazide, potassium citrate, metabolic alkalosis, nephrolithi-
with nephrolithiasis. The present study indicates thatasis.
hypokalemia does not develop during long-term thiazide
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Table 1. Study population and treatmentMETHODS
Group 1 Group 2 Group 3Study population
N  50 N  23 N  22
All patients were selected from three stone clinics at
Patients
the University of Texas Southwestern Medical Center, Males 41 18 12
Females 9 5 10Dallas, Texas (group 1), Duke University Medical Cen-
Age years, mean (range) 48 (15–75) 47 (27–66) 55 (32–77)ter, Durham, North Carolina (group 2), and the Ochsner
Treatment dose meanSD
Clinic, New Orleans, Lousiana (group 3) and satisfied Trichlormethiazide mg/day 31 31
Hydrochlorothiazide mg/day 5318 50 3425five criteria: (1) idiopathic calcium oxalate nephrolithia-
Urocit-K mEq/day 4016 408 5219sis, defined as calcium oxalate stone formation, without
Duration of treatment months,
evidence of chronic diarrheal syndrome, primary hyper- mean (range) 27 (12–36) 19 (4–50) 35 (12–81)
parathyroidism, complete distal renal tubular acidosis,
cystinuria, or infection stones; (2) persistent or intermit-
tent hypercalciuria that was thought sufficient to qualify
for thiazide treatment; (3) absence of hypokalemia, hy- NJ, USA) but were later switched to the generic prepara-
perkalemia or predisposition to hyperkalemia (such as tions when they became available. A tablet formulation
type IV renal tubular acidosis or treatment with angio- of potassium citrate (Urocit-K, 10 mEq tablets in wax
tensin-converting enzyme inhibitors or large doses of matrix, Mission Pharmacal Co., San Antonio, TX, USA)
nonsteroidal anti-inflammatory agents); (4) normal renal was used. Six patients who took hydrochlorothiazide took
function (creatinine clearance, obtained from fasting se- amiloride as well (Moduretic, Merck & Co., Inc., West
rum and 24-hour urinary creatinine at initial evaluation, Point, PA, USA).
of greater than 0.7 mL/min/kg); and (5) concurrent ad-
Statistical analysisministration of thiazide and potassium citrate (begun
together) for at least 1 year from group 1, and at least Repeated analysis of variance was used to test for
4 months from groups 2 and 3. Patients from group 1 significant changes between pretreatment and treatment
were generally followed every 4 months during treat- periods. Significant difference between two values before
ment, whereas those from groups 2 and 3 were typically and after treatment was assessed by paired t test. Since
followed every 6 months. No one with side effects to there was no study site interaction, results from the three
treatment was excluded. groups were combined. A combination of thiazide (50 mg)
and amiloride (5 mg) typically produces a milder degree
Laboratory analysis of hypokalemia without potassium supplementation. Ex-
For patients from all three groups, fasting venous clusion of six patients on this combination did not alter
blood samples for measurement of sodium, potassium, the results. Thus, data in all patients were presented.
chloride, and bicarbonate were drawn before treatment
and at each follow-up treatment visit. At each institution,
RESULTSthe above tests were obtained from Clinical Laboratory
Study population and treatmentImprovement Amendments (CLIA)-certified laboratories.
From group 1 only, 24-hour hour urine samples were Ninety-five patients were analyzed in this retrospective
collected for the measurement of complete urinary stone analysis comprising 50 patients from group 1, 23 from
risk factors, which included potassium, pH, citrate, so- group 2, and 22 from group 3 (Table 1). The cause of
dium and chloride, using methods previously described hypercalciuria was rigorously sought with “fast and cal-
[9]. From the urinary biochemical data, net gastrointesti- cium load test” [12] and serum parathyroid hormone
nal absorption of alkali [10] and titratable acidity were (PTH) only in group 1. Forty-four of 50 patients from
calculated [11]. All 24-hour urine samples were collected group 1 had absorptive hypercalciuria. The remaining
with the patients on ad libitum outpatient diets. six patients had persistent or intermittent hypercalciuria
of undetermined origin, along with gouty diathesis in
Drug and dose selection three and hypercalciuric calcium oxalate nephrolithiasis
in three. In groups 2 and 3, the cause of hypercalciuriaThe physicians caring for the patients chose the type
and dose of thiazide, based on their experience in manag- was not established as precisely. The majority of patients
were men (Table 1). Mean dose and duration of treat-ing hypercalciuria. Physicians also selected the dose of
potassium citrate from their perception of the amount ment are summarized in Table 1. In group 1, 31 patients
were on trichlormethiazide at an average dose of 3.0 mg/required to prevent hypokalemia and hypocitraturia.
Generic preparations of hydrochlorothiazide were gen- day, and 19 were taking hydrochlorothiazide 53 mg/day,
six of them with amiloride 5 mg/day. In group 2, 22erally used. Some patients initially received the brand form
of trichlormethiazide (Naqua, Schering Corp., Kenilworth, patients were on trichlormethiazide at an average dose
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Table 2. PTH, serum calcium and serum electrolytes before and during combined treatment with Urocit-K and thiazide
Treatment duration months
Baseline 4–6 8–12 18–24 24
Sodium mEq/L 1403 1403 1402 1402 1402
Potassium mEq/L 4.150.36 4.200.39 4.190.37 4.200.38 4.120.35
Chloride mEq/L 1033 1023b 1023c 1023c 1023b
Bicarbonate mEq/L 26.22.5 26.52.7 26.92.7a 27.12.6c 26.92.6
Calcium mg/dL 9.50.3
Parathyroid hormone
Mid moleculed pg/mL 275126
Intacte pg/mL 3617
Data presented as meanSD. Statistical significance from baseline indicated by
a P  0.05; b P  0.01, and c P  0.005
d Normal value 100–400 pg/mL
e Normal value: 10–65 pg/mL
Fig. 1. Individual serum potassium values during combined treatment with thiazide and potassium citrate. Majority of the values were within
normal limits. Thirteen determinations (from six patients) were less than 3.5 mEq/L. The patient who had persistent hypokalemia from months
8 to 32 was taking a large dose of hydrochlorothiazide (100 mg/day) and had both absorptive hypercalciuria and incomplete renal tubular acidosis.
Dashed horizontal lines indicate the normal range. Individual points are depicted. Some points appear darker than others because of close similarity
in values among several samples.
of 3 mg/day, and one was on hydrochlorothiazide 50 mg/ and remained within normal limits throughout the com-
bined treatment with potassium citrate and thiazide (Ta-day. In group 3, all 22 patients were on hydrochlorothia-
zide at an average dose of 34 mg/day. Mean dose of ble 2). Serum calcium and PTH measured in 45 patients
at baseline were within normal limits. Individual potas-potassium citrate was 40 mEq/day for groups 1 and 2.
Despite a lower dose of thiazide, the dose of potassium sium values are presented in Figure 1. At baseline, two
patients had hypokalemia (3.5 mEq/L), and no onecitrate was slightly higher at 52 mEq/day in group 3. The
duration of thiazide-potassium citrate treatment ranged had a potassium concentration 5.2 mEq/L. Of 414 de-
terminations from 95 patients during repeat follow-upfrom 4 to 81 months; mean duration ranged from 19 to
35 months at the three sites. visits, serum potassium concentration was below 3.5
mEq/L in 13 determinations (from six patients). In five
Serum chemistries of these patients, hypokalemia was corrected with in-
creased dose of potassium citrate. Only one patient hadSerum data from the three centers were pooled and
analyzed. Mean serum potassium was normal at baseline persistently low potassium concentration (in months 8
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Fig. 2. Individual serum chloride values during combined treatment with thiazide and potassium citrate. During combined therapy, the majority
of the patients remained normochloremic. Only five patients developed transient decrease in serum chloride concentration, and six had serum
chloride concentrations 108 mEq/L. Dashed horizontal lines indicate the normal range.
to 32). This patient had absorptive hypercalciuria and tration. Among 401 determinations from all 95 patients
during combined treatment, three determinations fromincomplete distal renal tubular acidosis and was taking
100 mg hydrochlorothiazide/day. Eventually, hypokalemia two patients were low, and six determinations from four
patients were 32 mEq/L.was corrected when the dose of potassium citrate was
increased to 100 mEq per day. Among 414 determina- Results were indistinguishable when six patients who
took amiloride were excluded compared with data fromtions during follow-up visits, only one potassium deter-
mination (from one patient) was greater than 5.2 mEq/L. all patients. Similar trends were observed among the
threee groups even though patients in group 3 receivedMean serum chloride was slightly and significantly
lower by 1 mEq/L from baseline, but remained within relatively lower dose of thiazide and higher dose of po-
tassium citrate (Table 1). There was no significant changenormal limits during combined thiazide-potassium ci-
trate therapy (Table 2). Individual values are plotted in serum sodium concentration during combined treat-
ment compared to baseline (Table 2).over varying periods of treatment in Figure 2. Before
treatment, one patient had hypochloremia (serum chlo-
Urinary chemistriesride 95 mEq/L) and two patients had high serum chlo-
ride concentration (108 mEq/L). Among 413 samples Pertinent urinary chemistries, available from group 1
only, are presented in Table 3. Compared with pretreat-during combined treatment with thiazide and potassium
citrate, seven determinations (from five patients) were ment, combined treatment with thiazide and potassium
citrate produced a significant and sustained rise in uri-low and seven determinations from six patients were
above 108 mEq/L. nary pH, citrate, and potassium. Urinary potassium in-
creased by an average of 40 mEq, approximating theMean serum bicarbonate (total carbon dioxide) con-
centration was slightly and significantly higher compared amount of potassium given as replacement. Urinary pH
increased by an average of 0.55 and was maintainedto pretreatment value at 8 to 12 months and 18 to 24
months of combined thiazide-potassium treatment, but between 6.3 and 6.5. The mean increase in urinary citrate
was 209  45 mg during combined therapy. Urinarywas not significantly different from baseline at other
treatment periods (Table 2). All mean serum bicarbon- sodium and chloride did not significantly change during
combined therapy.ate concentrations remained within normal limits during
the entire period of combined treatment. Individual val- Urinary chloride was measured in most (N  38) but
not all patients or visits from group 1. Thus, the netues are shown in Figure 3. At baseline, one determina-
tion from one patient was low (20 mEq/L). None of gastrointestinal alkali absorption and titratable acidity
could not be calculated in some patients or visits. Urinarythe patients had high (32 mEq/L) bicarbonate concen-
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Fig. 3. Individual serum bicarbonate [total carbon dioxide (CO2)] concentrations during combined treatment with thiazide and potassium citrate.
Most of the values were within normal limits during combined therapy. Only three out of 401 determinations were20 mEq/L and six determinations
from four patients were 32 mEq/L. The dashed horizontal lines indicate the normal range.
given with thiazide may be ineffective in averting hypo-
kalemia and may produce hypochloremic metabolic al-
kalosis [8]. This retrospective analysis from 95 patients
with calcium oxalate stones at three established stone
clinics indicate that neither complication occurs during
long-term combined treatment with thiazide and potas-
sium citrate. Thiazide reduces urinary calcium excretion
by its indirect effect from extracellular volume contrac-
tion and its primary stimulation of distal renal tubular
reabsorption of calcium through unresolved mechanisms
[13, 14]. This “hypocalciuric” action renders thiazide an
effective agent in the management of hypercalciuric cal-
cium oxalate nephrolithiasis. A review by Coe of ran-
domized trials indicated inhibition of stone recurrence
by thiazide [15].
Fig. 4. Individual urinary chloride concentrations before and during Recent studies disparaging the role of dietary calcium
treatment. Urinary chloride concentration was rarely (three out of 154
restriction in stone formation should not detract fromdeterminations) below 15 mEq/L during combined therapy.
the ability of thiazide to inhibit stone formation. Borghi
et al found a low protein-sodium diet to be more effective
than low calcium diet in inhibiting stone formation [16].chloride concentration was rarely below 15 mEq/L (3 of
Several epidemiological studies by Curhan et al [17, 18]154 determinations from three patients during combined
among subjects without stones indicated that high cal-thiazide-potassium citrate treatment). Compared with
cium diet may be protective against stone formation.pretreatment, net gastrointestinal alkali absorption sig-
These studies indicating negative effect of dietary cal-nificantly increased while titrable acidity decreased sig-
cium restriction were attributed to the concurrent in-nificantly during combined treatment (Table 3).
crease in urinary oxalate. However, no one disputes the
fact that hypercalciuria increases the risk for calcium
DISCUSSION oxalate stone formation [19, 20]. Curhan et al reported
that hypercalciuria carried a high risk for stone formationThis study was prompted by a long-held concern that
nonchloride potassium salt such as potassium citrate among patients with stones [21]. The advantage of thia-
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zide is that it can reduce urinary calcium without affect-
ing urinary oxalate [22].
Despite the utility of thiazide in the management of
hypercalciuric calcium oxalate nephrolithiasis, its kaliur-
etic effect mandates concomitant potassium replacement
with its use. Because of the urinary alkalinizing and citra-
turic effects [23], citrate is the preferred anion for admin-
istering potassium when treating hypercalciuric patients
with thiazide. Previous placebo-controlled randomized
trials have shown that potassium alkali can decrease stone
recurrence rate in patients with idiopathic hypocitraturic
calcium nephrolithiasis [24, 25].
However, two potential complications of combined
treatment with thiazide and potassium citrate have been
raised. First, while the administration of alkali to normal
subjects results in bicarbonaturia with no rise in serum
bicarbonate, the same dose of alkali when given to indi-
viduals with diuretic-induced volume contraction might
result in alkali retention and metabolic alkalosis [26].
Although this may be a potential complication of combi-
nation thiazide-potassium citrate therapy for patients
with hypercalciuria, available data failed to show meta-
bolic alkalosis during combined therapy [27, 28]. Reten-
tion of exogenously administered alkali occurs under
nonphysiologic maneuvers involving gastric suction and/or
very low sodium diets [29, 30]. In this study of patients
with nephrolithiasis, we used a less potent thiazide.
Moreover, severe sodium restriction is practically impos-
sible to achieve in the outpatient setting over months
among patients with stones.
Second, Atkins and Schwartz, in experimental animals
[31], and Kassirer et al, in human subjects [8], have noted
that it is not possible to correct hypokalemic hypochlore-
mic alkalosis with potassium administration unless chlo-
ride is provided. These investigators proposed that the
reduced delivery of chloride from a nonchloride potas-
sium salt would impair the renal tubular reabsorption
of sodium as sodium chloride, favoring hydrogen and
potassium excretion, which would perpetuate or acceler-
ate the metabolic alkalosis and persistent hypokalemia.
A later study by Carlisle et al showed that the poorly
reabsorbable anions such as sulfate or bicarbonate in-
crease renal potassium secretion [32]. When the urinary
concentration of chloride was greater than 15 mEq/L,
sulfate does not increase renal potassium excretion but
bicarbonate can still be kaliuretic. In this study, and gen-
erally in stone patients on normal diets, urinary chloride
is greater than this value in the vast majority of patients
(Fig. 4). Urinary chloride concentration less than 15 mEq/L
would be expected to occur only among patients with
intractable or severe vomiting, diarrhea, or sweating.
Nonetheless, since these concerns have been raised,
we conducted this retrospective analysis of data from three
centers to determine if the use of potassium citrate with
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a thiazide diuretic is effective in preventing hypokalemia, acknowledge that this is not unusual in clinical practice
because of variable individual response to treatment. Ifand whether metabolic alkalosis is encountered.
In patients who have been on treatment for at least there is a dose effect, we should have seen a between-group
difference in serum electrolyte changes on combined4 to 81 months (a mean of 19 to 35 months at three cen-
ters), serum potassium concentration remained within therapy. This was not evident when the data from the
three groups were analyzed separately (data not shown).normal limits in majority (90%) of the patients during
potassium citrate supplementation. This finding supports In summary, the present study provides evidence that
administration of potassium citrate can effectively main-our contention that potassium citrate prevents diuretic-
induced hypokalemia. This finding had been reported be- tain normokalemia and does not lead to metabolic alka-
losis during long-term thiazide therapy for hypercalciuricfore in a randomized short-term treatment trial [28, 33],
as well as in a long-term trial [27]. We have shown in pre- nephrolithiasis.
vious studies that hypokalemia would have developed if
thiazide is administered without potassium citrate sup- ACKNOWLEDGMENTS
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